Chemistry:Glypromate
From HandWiki
Glypromate (Gly-Pro-Glu, GPE) is a tripeptide fragment derived from the N-terminus of the endogenous growth factor IGF-1. It has antiinflammatory and neuroprotective effects and is of interest in the treatment of neurological conditions such as Alzheimer's disease and Parkinson's disease. The simple GPE peptide has poor blood-brain barrier penetration and is rapidly metabolised in the body, however a number of synthetic derivatives of GPE have been developed with improved properties.[1][2][3][4][5][6][7][8][9][10]
See also
- Cortagen
- Copper peptide GHK-Cu
- KPV tripeptide
- Livagen
- N-Acetylcysteine ethyl ester
- SVT-NH-ethyl
References
- ↑ "The biological role of truncated insulin-like growth factor-1 and the tripeptide GPE in the central nervous system". Annals of the New York Academy of Sciences 692 (1): 183–191. August 1993. doi:10.1111/j.1749-6632.1993.tb26216.x. PMID 8215022. Bibcode: 1993NYASA.692..183S.
- ↑ "Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury". Recent Patents on CNS Drug Discovery 3 (2): 112–127. June 2008. doi:10.2174/157488908784534630. PMID 18537771.
- ↑ "IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions". British Journal of Pharmacology 157 (6): 881–891. July 2009. doi:10.1111/j.1476-5381.2009.00256.x. PMID 19438508.
- ↑ "GPE and GPE analogues as promising neuroprotective agents". Mini Reviews in Medicinal Chemistry 12 (1): 13–23. January 2012. doi:10.2174/138955712798868995. PMID 22070686.
- ↑ "Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer's Disease". Biomolecules 11 (1): 126. January 2021. doi:10.3390/biom11010126. PMID 33478054.
- ↑ "Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences". ACS Chemical Neuroscience 14 (4): 554–572. February 2023. doi:10.1021/acschemneuro.2c00675. PMID 36735764.
- ↑ "Exploring structural determinants of neuroprotection bias on novel glypromate conjugates with bioactive amines". European Journal of Medicinal Chemistry 267. March 2024. doi:10.1016/j.ejmech.2024.116174. PMID 38306884.
- ↑ "[Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.]". Advances in Gerontology = Uspekhi Gerontologii 37 (1–2): 10–20. 2024. PMID 38944767.
- ↑ "Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review". International Journal of Medical Sciences 22 (16): 4175–4200. 2025. doi:10.7150/ijms.118118. PMID 41209547.
- ↑ "Rational Design of Dual-Targeting Novel GPE-Derived Oligopeptide Conjugates for Alzheimer's Disease: Synergistic Inhibition of Excitotoxicity and Oxidative Stress". ACS Chemical Neuroscience 17 (4). February 2026. doi:10.1021/acschemneuro.5c00871. PMID 41641951.
 |  |
